Gynecologic Cancer
EC145 in Combination With Doxil® for Platinum Resistant Ovarian Cancer (7334)
Protocol EC-FV-06: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (Pld/Doxil®/Caelyx®) In Combination Versus PLD In Participants with Platinum-Resistant Ovarian Cancer
Investigator: Barbara Ann Goff, MD; Conditions: Ovarian Cancer; Status: Recruiting; Study ID: NCT01170650
A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Investigator: Benjamin Greer, MD; Conditions: Gynecological Cancer; Ovarian Cancer; Solid Tumors; Uterine Cancer; Status: Recruiting; Study ID: NCT00954174
A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (NSC# 704865, IND#7921) in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer
Investigator: Benjamin Greer, MD; Conditions: Fallopian Cancer, Ovarian Cancer, Peritoneal Cancer; Status: Recruiting; Study ID: NCT01167712
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Investigator: Benjamin Greer, MD; Conditions: Cervical Cancer; Status: Recruiting; Study ID: NCT00980954
A Randomized Phase III Trialof Cisplatin and Tumor Volume Directional Irradiation Followed By Carboplatin and Paclitaxel Vs.for Optimally Debulked, Advanced Endometrial Carcinoma
Investigator: Benjamin Greer, MD; Conditions: Endometrial Cancer; Status: Recruiting; Study ID: NCT00942357
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma
Investigator: Benjamin E. Greer, MD; Conditions: Endometrial Cancer, Fatigue, Neurotoxicity; Status: Recruiting; Study ID: NCT00807768
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
Investigator: Benjamin E. Greer, MD; Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer; Status: Recruiting; Study ID: NCT00565851
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
Investigator: Benjamin E. Greer, MD; Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer; Status: Recruiting; Study ID: GOG+0212
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors
Investigator: Scott S. Tykodi, MD, PhD; Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer, Colorectal Adenocarcinoma; Status: Recruiting; Study ID: NCT00729664
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer
Investigator: Barbara A. Goff, MD; Conditions: Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma; Status: Recruiting; Study ID: NCT01091428
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Investigator: Shailender Bhatia, M.D; Conditions: Ovarian Cancer, Merkel Cell Carcinoma, Small Cell Lung Cancer; Status: Closed; Study ID: NCT00346385
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC#704865, IND#7921), Paclitazel/Carboplatin/Temsirolimus (NSC#683864, IND#61010) and Ixabepilone (NSC#710428, IND#59699) Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Investigator: Benjamin Greer, MD; Conditions: Endometrial Cancer; Status: Recruiting; Study ID: NCT00977574
FDG PET and Biomarkers in Treatment Response in Advanced Ovarian Cancer
Investigator: Dr. Joseph Rajendran; Conditions: Advanced Ovarian Cancer; Status: Recruiting
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors
Investigator: Heidi J. Gray, MD; Conditions: Advanced Solid Tumors; Status: Not Recruiting; Study ID: NCT01063816
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Investigator: Shailender Bhatia, M.D; Conditions: Ovarian Cancer, Merkel Cell Carcinoma, Small Cell Lung Cancer; Status: Closed; Study ID: NCT00346385
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC#683864, IND#61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Investigator: Benjamin Greer, MD; Conditions: Ovarian Cancer; Status: Recruiting; Study ID: NCT01196429
A Phase II Evaluation of VEGF-Trap (Aflibercept, NSC# 724770, IND #BB100137, NCI Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Investigator: Benjamin Greer, MD; Conditions: Endometrial Cancer, Gynecological Cancer; Status: Closed; Study ID: NCT00462826
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Investigator: Benjamin Greer, MD; Conditions: Fallopian Cancer, Ovarian Cancer, Primary Peritoneal Cancer (PPC); Status: Recruiting; Study ID: NCT00888615
Join Us On